Article in Alcoholism, clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Elliot B TapperFrom the, Division of Gastroenterology and Hepatology, (EBT, NDP), Department of Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-0839-1515
Neehar D ParikhFrom the, Division of Gastroenterology and Hepatology, (EBT, NDP), Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, (SL), Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
University of Michigan · US
Funding
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating CenterU24AA026969 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI SAMER GAWRIEH, WANZHU TU · 2018 to 2026
$20.2M
Novel biomarkers as a clinical tool for excessive alcohol use screeningR01AA025208 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT, TU, WANZHU · 2016 to 2020
$1.7M
Sestrin3 in the pathogenesis of alcoholic and non-alcoholic fatty liver diseaseR01DK107682 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE, LIANGPUNSAKUL, SUTHAT · 2016 to 2019
$1.4M
Immunological Profiles and prognostic outcomes in patients with alcoholic hepatitisU01AA026917 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2022
$1.2M
Optimizing Measures for Clinical Trials in Covert Hepatic EncephalopathyK23DK117055 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAPPER, ELLIOT · 2019 to 2022
$776k
Novel animal models to study miRNA-mediated alcoholic liver diseaseUH2AA026903 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2019
$447k
Serum Proteomic Profiles as Biomarkers of Abusive Alcohol ConsumptionI01CX000361 · VA · RLR VA MEDICAL CENTER · PI LIANGPUNSAKUL, SUTHAT · 2012 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales. · full record | OpenQuestion